Use of Fluticasone Propionate/Salmeterol Combination Post Emergency Department Visit
Information source: GlaxoSmithKline
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Asthma
Intervention: Fluticasone propionate/salmeterol combination ED MD (Drug); Fluticasone propionate/salmeterol combination OP MD (Drug)
Phase: N/A
Status: Completed
Sponsored by: GlaxoSmithKline Official(s) and/or principal investigator(s): GSK Clinical Trials, Study Director, Affiliation: GlaxoSmithKline
Summary
The objective of this study is to compare readmission to the emergency department for asthma
in asthma patients who receive treatment with fluticasone propionate and salmeterol oral
inhaler after an initial emergency department visit using a retrospective observational
cohort study design.
Clinical Details
Official title: Use of Fluticasone Propionate/Salmeterol Combination Post Emergency Department Visit
Study design: Observational Model: Cohort, Time Perspective: Retrospective
Primary outcome: Number of Participants With an Asthma-related Event Occurring Between 1 and 6 Months Following the Index Event
Eligibility
Minimum age: 12 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Subjects with asthma as determined by ICD-9 codes and asthma drug use
- at least 12 years of age
- discharged from an initial Emergency Department visit within 12 months
Exclusion Criteria:
- Subjects with COPD or treatment for COPD
Locations and Contacts
Additional Information
Starting date: June 2009
Last updated: October 20, 2011
|